Logo Logo
Exportieren als [RSS feed] RSS 1.0 [RSS2 feed] RSS 2.0
Gruppiert nach: Dokumententyp | Veröffentlichungsdatum
Springe zu: 2025 | 2024 | 2022
Anzahl der Publikationen: 8

2025

Tomsitz, Dirk; Grabmaier, Ulrich; Spiro, Judith; Nicolai, Leo ORCID logoORCID: https://orcid.org/0000-0003-0776-5885; French, Lars E. ORCID logoORCID: https://orcid.org/0000-0002-4629-1486; Massberg, Steffen ORCID logoORCID: https://orcid.org/0000-0001-7387-3986 und Heinzerling, Lucie ORCID logoORCID: https://orcid.org/0000-0001-5718-3643 (5. Februar 2025): Optimized monitoring for immune checkpoint inhibitor induced myocarditis using high-sensitivity troponin-T. In: European Journal of Cancer, Bd. 216, 115186 [PDF, 1MB]

Tomsitz, Dirk; Zimmermann, Petra; Kunz, Wolfgang G. ORCID logoORCID: https://orcid.org/0000-0002-5021-1952; Neumann, Jens; Siegmund, Birte J.; Weiss, Bernhard G. ORCID logoORCID: https://orcid.org/0000-0002-8368-0149; Kauke, Teresa ORCID logoORCID: https://orcid.org/0000-0001-6569-9703; Sienel, Wulf; French, Lars E. ORCID logoORCID: https://orcid.org/0000-0002-4629-1486; Klauschen, Frederick ORCID logoORCID: https://orcid.org/0000-0002-9131-2389 und Heinzerling, Lucie ORCID logoORCID: https://orcid.org/0000-0001-5718-3643 (2025): Neoadjuvant treatment with immune checkpoint inhibitors in patients with melanoma: A real‐life retrospective study. In: JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Bd. 23, Nr. 5: S. 600-608

2024

Tomsitz, Dirk; Kerl, Katrin; French, Lars Einar ORCID logoORCID: https://orcid.org/0000-0002-4629-1486 und Heinzerling, Lucie ORCID logoORCID: https://orcid.org/0000-0001-5718-3643 (2024): Clinical and pathological characterization of tebentafusp-associated skin toxicity: A cohort study with 33 patients. In: Journal of the American Academy of Dermatology, Bd. 91, Nr. 6: S. 1136-1142 [PDF, 1MB]

2022

Zierold, Sarah; Akcetin, Larissa Semra; Gresser, Eva; Maier, Anna Marie; König, Alexander; Kramer, Rafaela; Theurich, Sebastian; Tomsitz, Dirk; Erdmann, Michael; French, Lars E.; Rudelius, Martina und Heinzerling, Lucie ORCID logoORCID: https://orcid.org/0000-0001-5718-3643 (2022): Checkpoint-inhibitor induced Polyserositis with Edema. In: Cancer Immunology Immunotherapy, Bd. 71, Nr. 12: S. 3087-3092 [PDF, 658kB]

Schulz, Thomas U.; Zierold, Sarah; Sachse, Michael M.; Pesch, Giulia; Tomsitz, Dirk; Schilbach, Katharina; Kahler, Katharina C.; French, Lars E. und Heinzerling, Lucie (2022): Health-related quality of life (EuroQol 5D-5L) in patients with autoimmunity in the context of immunotherapy: A large dataset comprising cancer patients after cessation of checkpoint inhibitor therapy and patients with autoimmune diseases. In: Data in Brief, Bd. 45, 108676 [PDF, 312kB]

Tomsitz, Dirk; Schlaak, Max; Zierold, Sarah; Pesch, Giulia; Schulz, Thomas U.; Müller, Genoveva; Zecha, Christine; French, Lars E. und Heinzerling, Lucie (2022): Development of Lymphopenia during Therapy with Immune Checkpoint Inhibitors Is Associated with Poor Outcome in Metastatic Cutaneous Melanoma. In: Cancers, Bd. 14, Nr. 13 [PDF, 634kB]

Cartun, Zachary; Kunz, Wolfgang G.; Heinzerling, Lucie; Tomsitz, Dirk; Guertler, Anne; Westphalen, C. Benedikt; Ricke, Jens; Weir, William; Unterrainer, Marcus und Mehrens, Dirk (2022): Cost-effectiveness of Response-Adapted De-escalation of Immunotherapy in Advanced Melanoma. In: JAMA Dermatology, Bd. 158, Nr. 12: S. 1387-1393

Schulz, Thomas U.; Zierold, Sarah; Sachse, Michael M.; Pesch, Giulia; Tomsitz, Dirk; Schilbach, Katharina; Kaehler, Katharina C.; French, Lars E. und Heinzerling, Lucie (2022): Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life. In: European Journal of Cancer, Bd. 176: S. 88-99

Diese Liste wurde am Sat Jul 12 23:38:51 2025 CEST erstellt.